Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. [electronic resource]
- Nature reviews. Clinical oncology Oct 2010
- 600-3 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1759-4782
10.1038/nrclinonc.2010.141 doi
Cancer Vaccines--therapeutic use Female Fusion Proteins, bcr-abl--blood Humans Interferon-alpha--therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive--blood Middle Aged Vaccination